A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation

Thomas Fong, Kathryn Trinkaus, Douglas Adkins, Ravi Vij, Steven M. Devine, Michael Tomasson, Lawrence T. Goodnough, Sandra Lopez, Timothy Graubert, Shalini Shenoy, John F. DiPersio, Hanna J. Khoury

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD). In a single-institution phase III trial, 95 recipients of allogeneic peripheral blood stem cell (PBSC) transplantation were randomized to receive, in a double-blind fashion, and in addition to prophylactic cyclosporine A (CSA), HCQ, or placebo starting 21 days pretransplant and continued until day +365. HCQ was very well tolerated and not associated with side effects. Overall, the incidence of acute GVHD (aGVHD) was 59% in both arms, and severe aGVHD occurred in 11% (HCQ) and 14% (placebo) (P = .76). Sixty percent and 78% of patients developed chronic GVHD (cGVHD) in the HCQ and the placebo arms, respectively (P = .15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival.

Original languageEnglish
Pages (from-to)1201-1206
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume13
Issue number10
DOIs
StatePublished - Oct 2007

Keywords

  • Chronic GVHD
  • Hydroxycholorquine
  • Propyhlaxis

Fingerprint

Dive into the research topics of 'A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation'. Together they form a unique fingerprint.

Cite this